Targeted Therapies for Cancer: ImmunoGen, Inc.

Site Map

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

T-DM1 is in Phase III testing, and 6 other compounds are in clinical testing through our own programs and those of our partners.

See which compounds are in the clinic...

We and our partners had a number of presentations at the ASCO and AACR annual meetings.

Find out more about these...

9/2/2010
ImmunoGen, Inc. Announces Webcast of Presentations at Multiple Investor Conferences in September

8/27/2010
Genentech Receives Refuse to File Letter from FDA for T-DM1

Read our releases...

built@zoomedia.com

Last updated September 2, 2010